How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

12,200 results for

Prostate Cancer Staging

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline

Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline - American Urological Association advertisement Toggle navigation About Us AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors Penis Retroperitoneum Cytology Online Learning For Medical Students Exams/LLL (...) are challenged to remain up-to-date and informed with respect to a multitude of treatment options for patients with advanced prostate cancer. To assist in clinical decision-making, evidence-based guideline statements were developed to provide a rational basis for evidence-based treatment. This guideline covers advanced prostate cancer, including disease stages that range from prostate-specific antigen (PSA) recurrence after exhaustion of local treatment options to widespread metastatic disease. Methodology

2020 American Urological Association

182. Bone Health and Bone-targeted Therapies for Prostate Cancer

for Prostate Cancer guideline. This guideline included recommendations across a relatively broad clinical spectrum within prostate cancer. Topics addressed ranged from management of osteoporotic fracture risk in nonmetastatic disease to management of men with castration-resistant prostate cancer metastatic to bone. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. METHODS The Bone Health and Bone-Targeted (...) -targeted therapies for prostate cancer. The CCO practice recommendations are drawn from data provided by randomized controlled trials (RCT) and systematic reviews of bone-targeted therapies in men with prostate cancer in a variety of settings. Relevant clinical risks range from osteoporotic fractures associated with androgen-deprivation therapy (ADT) to morbidity and death as a result of progression of bone-metastatic castration-resistant disease. In this document, the ASCO Expert Panel (Appendix

2020 American Society of Clinical Oncology Guidelines

183. Effect of androgen deprivation therapy on intraprostatic tumour volume identified on 18F choline PET/CT for prostate dose painting radiotherapy Full Text available with Trip Pro

the effect of ADT on choline tracer uptake and boost volumes identified on choline PET/CT.Fluoroethylcholine (18F choline) PET/CT was performed for dose painting radiotherapy planning in patients with intermediate- to high-risk prostate cancer. Initially, they were performed at planning. Owing to low visual tracer uptake, PET/CT for subsequent patients was performed at staging. We compared these two approaches on intraprostatic lesions obtained on PET using both visual and automatic threshold methods (...) Effect of androgen deprivation therapy on intraprostatic tumour volume identified on 18F choline PET/CT for prostate dose painting radiotherapy Prostate dose painting radiotherapy requires the accurate identification of dominant intraprostatic lesions (DILs) to be used as boost volumes; these can be identified on multiparametric MRI (mpMRI) or choline positron emission tomography (PET)/CT. Planning scans are usually performed after 2-3 months of androgen deprivation therapy (ADT). We examine

2017 The British journal of radiology

184. Incidental Detection of Occult Thyroid Carcinoma with 11C-Choline PET/CT for High Risk Prostate Cancer Full Text available with Trip Pro

Incidental Detection of Occult Thyroid Carcinoma with 11C-Choline PET/CT for High Risk Prostate Cancer We report a case of a 65-year-old male patient with high-risk prostate cancer, re-staged with 11C-choline positron emission tomography/computed tomography (PET/CT) for prostate specific antigen recurrences 3 years after radical prostatectomy and adjuvant radiation therapy. In addition to 2 suspicious presacral lymph nodes which were resected and proven to be metastatic, PET/CT revealed a very (...) high uptake in a calcified thyroid nodule. Evaluation with fine needle aspiration was suspicious for thyroid carcinoma and the patient underwent total thyroidectomy, confirming a non-metastatic encapsulated follicular variant of papillary thyroid carcinoma. To our knowledge, this is the first report of a thyroid cancer diagnosed with 11C-choline PET/CT for prostate cancer staging.

2017 Current urology

185. External Beam Radiation and Brachytherapy for Prostate Cancer: Is It a Possible Trigger of Large Cell Neuroendocrine Carcinoma of the Urinary Bladder? Full Text available with Trip Pro

, and generally presents in an advanced stage with poor prognosis compared to transitional cell bladder carcinoma. There is no standardized treatment regimen because of the rarity of the disease. Herein, we present a case of 72-year-old male patient with previously treated prostate cancer, who received external beam radiation therapy and high dose brachytherapy, presenting with intermittent hematuria. Cystoscopy and transurethral resection of bladder tumor (TURBT) were performed. The histopathology (...) External Beam Radiation and Brachytherapy for Prostate Cancer: Is It a Possible Trigger of Large Cell Neuroendocrine Carcinoma of the Urinary Bladder? Neuroendocrine tumors commonly involve the respiratory and gastrointestinal systems. Primary genitourinary neuroendocrine tumors are rare, accounting for less than 1% of all bladder carcinomas. Four histopathologic subtypes have been described. Among those, large cell neuroendocrine carcinoma (LCNEC) is the least common, is more aggressive

2017 Case reports in oncological medicine

186. Racial Difference in Prostate Cancer Cell Telomere Lengths in Men with Higher Grade Prostate Cancer: A Clue to the Racial Disparity in Prostate Cancer Outcomes. Full Text available with Trip Pro

men were frequency matched on age, pathologic stage, and grade. We measured telomere lengths in cancer and CAS cells using a robust telomere-specific FISH assay. Tissue microarray and grade-specific distributional cutoff points without regard to race were evaluated.Among men with higher grade disease, the proportion of Black men (47.1%) with more variable cancer cell telomere lengths was 2.3-times higher (P = 0.02) than that in White men (20.6%). In contrast, among men with lower grade disease (...) , cancer cell telomere length variability did not differ by race. The proportion of men with shorter CAS cell telomeres did not differ by race for either higher or lower grade disease.A greater proportion of Black men with higher grade disease have an adverse prostate cancer cell telomere phenotype than White men with higher grade disease.Our findings suggest a possible explanation for the racial disparity in prostate cancer outcomes.©2020 American Association for Cancer Research.

2020 Cancer Epidemiology & Biomarkers and Prevention

187. Cost Effectiveness of the Oncotype DX Genomic Prostate Score for Guiding Treatment Decisions in Patients With Early Stage Prostate Cancer. (Abstract)

Cost Effectiveness of the Oncotype DX Genomic Prostate Score for Guiding Treatment Decisions in Patients With Early Stage Prostate Cancer. To determine the cost-effectiveness of using the Oncotype DX Genomic Prostate Score (GPS), a 17-gene expression assay that can be used to inform decisions regarding active surveillance (AS) vs immediate treatment.We developed a Markov model simulating 20-year outcomes for 65-year-old men with very low-, low-, or favorable intermediate-risk prostate cancer (...) intermediate-risk patients. On sensitivity analysis, findings were robust against a willingness-to-pay of $100,000 per QALY to variations in key model parameters, including the cost of annual management of AS, probability of exiting AS to treatment, cost of treatment, and probability of biochemical failure post-treatment. However, the cost-effectiveness was sensitive to small differences in the utility of AS and the utility of no evidence of disease post-treatment states.The use of the GPS was cost

2018 Urology

188. Ga68-prostate specific membrane antigen positron emission tomography and multiparametric magnetic resonance imaging for primary lymph node staging of intermediate to high risk prostate cancer: a systematic review and meta-analysis of diagnostic test accur

Ga68-prostate specific membrane antigen positron emission tomography and multiparametric magnetic resonance imaging for primary lymph node staging of intermediate to high risk prostate cancer: a systematic review and meta-analysis of diagnostic test accur Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied (...) . These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models, the decision to pool certain units of measurement for an outcome, the choice of effect measure, how subgroup variables are stratified etc. In order to assess the robustness of the findings of the meta-analysis, the analyses are re-run using the alternative options for each decision. If the results of both meta-analyses are similar, the results seem robust. When the conclusions of a meta

2020 PROSPERO

189. Impact of prostatic anterior fat pads with lymph node staging in prostate cancer Full Text available with Trip Pro

Impact of prostatic anterior fat pads with lymph node staging in prostate cancer Background: Several reports have revealed the presence of lymph nodes in the prostatic anterior fat pad (PAFP). To date, no study has described the characteristics of Taiwanese patients harboring PAFP lymph nodes with metastatic prostate cancer involvement. Method: Between December 2006 and May 2015, a total of 849 consecutive patients underwent robot-assisted laparoscopic radical prostatectomy with PAFP dissection (...) lymph nodes were associated with the clinical T stage, preoperative Gleason score, pathological T stage, and pathological N stage (p < 0.001). Patients with pathological seminal vesicle invasion and a higher surgical Gleason score also exhibited PAFP lymph node metastases (p < 0.005). Conclusion: Our data show that 9.0% of patients had PAFP lymph nodes and that 1.3% had prostate cancer metastases. Additionally, 0.6% of patients were upstaged because of positive metastases in PAFP lymph nodes

2018 Journal of Cancer

190. Prostate cancer

5-year survival rate is around 100% for local- and regional-stage prostate cancer, and around 30% for distant-stage prostate cancer (based on data from 2007 to 2013). Definition A malignant tumour of glandular origin, situated in the prostate. It is most commonly seen in older men; between 2011 and 2015 the median age at diagnosis in the US was 66 years. National Cancer Institute; Surveillance, Epidemiology, and End Results program (SEER). SEER stat fact sheets: prostate cancer. 2018 [internet (...) is the principal investigator of an R-21 NIH research grant investigating the tumour-mediated immune responses in African-American men with prostate cancer. Professor Department of Radiation Oncology University of Texas MD Anderson Cancer Center Houston TX Disclosures MSA declares that he has no competing interests. Peer reviewers Clinical Oncology Registrar St Luke's Cancer Centre Royal Surrey Hospital Guildford Surrey UK Disclosures EA has received consultation fees from the following organisations during

2018 BMJ Best Practice

191. Prostate cancer

5-year survival rate is around 100% for local- and regional-stage prostate cancer, and around 30% for distant-stage prostate cancer (based on data from 2007 to 2013). Definition A malignant tumour of glandular origin, situated in the prostate. It is most commonly seen in older men; between 2011 and 2015 the median age at diagnosis in the US was 66 years. National Cancer Institute; Surveillance, Epidemiology, and End Results program (SEER). SEER stat fact sheets: prostate cancer. 2018 [internet (...) is the principal investigator of an R-21 NIH research grant investigating the tumour-mediated immune responses in African-American men with prostate cancer. Professor Department of Radiation Oncology University of Texas MD Anderson Cancer Center Houston TX Disclosures MSA declares that he has no competing interests. Peer reviewers Clinical Oncology Registrar St Luke's Cancer Centre Royal Surrey Hospital Guildford Surrey UK Disclosures EA has received consultation fees from the following organisations during

2018 BMJ Best Practice

192. Extended Cancer Education for Longer-Term Survivors in Primary Care for Patients With Stage I-II Breast or Prostate Cancer or Stage I-III Colorectal Cancer

tests four different methods of educating patients about follow-up care (NCI facing forward, brochure, EXCELS website alone, EXCELS health coaching alone and EXCELS website & health coaching combination) after cancer treatment ends. While it is known that patients need information to guide follow-up it remains unknown how to best provide this in primary care. Condition or disease Intervention/treatment Phase Stage I Breast Cancer Stage I Colorectal Cancer AJCC v6 and v7 Stage I Prostate Cancer Stage (...) Program) ) Pro2013003309 131318 ( Other Identifier: Rutgers Cancer Institute of New Jersey ) First Posted: July 28, 2017 Last Update Posted: August 9, 2018 Last Verified: August 2018 Additional relevant MeSH terms: Layout table for MeSH terms Breast Neoplasms Prostatic Neoplasms Colorectal Neoplasms Colonic Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Genital Neoplasms, Male Urogenital Neoplasms Genital Diseases, Male Prostatic Diseases Intestinal Neoplasms Gastrointestinal

2017 Clinical Trials

193. National Clinical Guideline for the Diagnosis, Staging and Treatment of Prostate Cancer

, staging and treatment of patients with prostate cancer Cancer is a major healthcare challenge. Each year in Ireland, approximately 19,000 people are diagnosed with malignant cancer. Cancer is the second leading cause of death in Ireland after diseases of the circulatory system. Deaths from cancer averaged about 8,800 deaths per year during 2010-2012, representing about 30% of all deaths in that period (NCRI, 2014a). Cancer incidence data from the National Cancer Registry Ireland (NCRI) and population (...) ) addressed this question. However, there is a lack of consensus elucidating which patient groups should have an MRI for staging. MRI is now the most commonly used imaging technique for T-staging men with prostate cancer. (NICE, 2014) The accuracy of staging of the disease may be improved by MRI which can reduce unnecessary treatment-related morbidity when there is no possibility of cure (Sanchez-Chapado et al., 1997, Bates et al., 1997). Multiparametric MRI may add additional information and can help

2015 Health Service Executive (Ireland) - Clinical Guidelines

194. Brachytherapy for Patients with Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update

Brachytherapy for Patients with Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update Genitourinary Cancer | ASCO Search form Search ASCO Family of Sites ASCOconnection.org features blogs from ASCO members, the online version of the membership magazine, a discussion area, working groups, and links to the ASCO Membership Directory, Career Center, and Volunteer Portal. ASCO’s growing roster of cutting-edge journals serves readers as the most credible (...) at every stage of their careers. A cutting-edge health information technology platform, CancerLinQ™ enables practitioners to learn from individual patients. By assembling vast amounts of usable, searchable, real-world data, CancerLinQ seeks to improve the quality and value of cancer care. Cancer.Net brings the expertise and resources of ASCO to people living with cancer and those who care for and about them to help patients and families make informed health care decisions. The Conquer Cancer Foundation

2017 Cancer Care Ontario

195. Incidental prostate cancer in Asian men: High prevalence of incidental prostatic adenocarcinoma in Chinese patients undergoing radical cystoprostatectomy for treatment of bladder cancer and selection of candidates for prostate-sparing cystectomy. Full Text available with Trip Pro

Incidental prostate cancer in Asian men: High prevalence of incidental prostatic adenocarcinoma in Chinese patients undergoing radical cystoprostatectomy for treatment of bladder cancer and selection of candidates for prostate-sparing cystectomy. Previous studies report a low prevalence of incidental prostate cancer in Chinese patients (3-7%). We evaluated incidental prostatic adenocarcinoma (PCa) and urothelial carcinoma (UCa) involvement of the prostate in cystoprostatectomy specimens.We (...) the 95 patients with PCa, 19 (20%) had Gleason score of ≥7, nine (10%) had PCa tumor volume >0.5 cc, and eight (8.4%) had extracapsular extension. Of the 115 with prostatic UCa, 61 had prostatic urethra and/or periurethral prostatic duct involvement only, while 54 had prostatic stromal invasion. Age (odds ratio [OR] = 1.04, P = 0.001), increasing stage of bladder tumor (OR = 1.28, P = 0.005), multifocal tumors of bladder (OR = 3.22, P < 0.001), carcinoma in situ (CIS) in the bladder (OR = 5.52, P

2015 Prostate

196. Bone Marrow Synoptic Reporting for Hematologic Neoplasms Full Text available with Trip Pro

, and treatment of neoplastic bone marrow disease. Disease categories addressed included acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDSs), myeloproliferative neoplasms (MPNs), plasma cell disorders, Hodgkin lymphoma, and non-Hodgkin lymphoma (NHL). Although aplastic anemia (AA) is not neoplastic, it was also addressed because of its overlap with MDSs. The CAP Cancer Protocols have previously established a reporting foundation by adopting synoptic reporting (...) of the project. The practitioner is referred to existing recommendations, such as those outlined in the CAP Cancer Protocols. It became clear during the work on this guideline that one uniform set of data elements for all hematopoietic neoplasms was impractical. In addition, diagnostic bone marrow reporting poses unique challenges, particularly at initial diagnosis. Unlike solid tumors with identifiable, often single, mass lesions, bone marrow neoplasms may declare themselves indirectly via peripheral blood

2016 College of American Pathologists

197. Evaluation of clinical staging of the American Joint Committee on Cancer (eighth edition) for prostate cancer. (Abstract)

Evaluation of clinical staging of the American Joint Committee on Cancer (eighth edition) for prostate cancer. This study aimed to evaluate the eighth edition of the American Joint Committee on Cancer (AJCC) for clinical staging of prostate cancer based upon Surveillance, Epidemiology and, End Results (SEER) database.Patients diagnosed as prostate adenocarcinoma during 2004-2009 without any surgical treatment to the primary site were selected from the SEER registry. Excluded were cases (...) to subdivide T2 disease clinically. For patients with grade group 1, cT2a and cT1 could merge into one group. Organ-confined disease with PSA ≥ 20 ng/ml or grade group 5 should be separated from stage II.

2018 World journal of urology

198. Evaluation of the major changes in eighth edition of the American Joint Committee on Cancer pathological staging for prostate cancer treated with prostatectomy. Full Text available with Trip Pro

Evaluation of the major changes in eighth edition of the American Joint Committee on Cancer pathological staging for prostate cancer treated with prostatectomy. This study aimed to evaluate the major changes of the eighth edition of the American Joint Committee on Cancer (AJCC) pathologic staging for prostate cancer treated with radical prostatectomy. A total of 138,176 patients diagnosed with prostate adenocarcinoma undergoing radical prostatectomy were selected from the Surveillance (...) than AJCC IIIB. There was necessity to separate the disease with PSA≥20ng/ml or Gleason score grade group 5 from other organ-confined disease. The present study supported the scientificity of the eighth edition of AJCC pathologic staging for prostate cancer.

2017 PLoS ONE

199. Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate Cancer

treatment planning in patients with prostate cancer. Multiparametric MRI may be useful for evaluating the type of cancer in finding aggressive disease. Condition or disease Intervention/treatment Phase Prostate Carcinoma Procedure: Multiparametric Magnetic Resonance Imaging Phase 2 Detailed Description: PRIMARY OBJECTIVES: I. To estimate the diagnostic performance as quantified by the area under the ROC curve to detect aggressive prostate cancer. II. To develop a risk prediction model by incorporating (...) Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate Cancer Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2018 Clinical Trials

200. A three-gene DNA methylation biomarker accurately classifies early stage prostate cancer. Full Text available with Trip Pro

A three-gene DNA methylation biomarker accurately classifies early stage prostate cancer. We identify and validate accurate diagnostic biomarkers for prostate cancer through a systematic evaluation of DNA methylation alterations.We assembled three early prostate cancer cohorts (total patients = 699) from which we collected and processed over 1300 prostatectomy tissue samples for DNA extraction. Using real-time methylation-specific PCR, we measured normalized methylation levels at 15 frequently (...) /GSTP1/HAPLN3 logistic regression model, with an area under these curves of 0.97, which showed a sensitivity of 94%, and a specificity of 93% after external validation.We created and validated a multigene model for the classification of benign and malignant prostate tissue. With false positive and negative rates below 7%, this three-gene biomarker represents a promising basis for more accurate prostate cancer diagnosis.© 2019 Wiley Periodicals, Inc.

2019 Prostate

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>